Shearman Mark S 4
4 · Editas Medicine, Inc. · Filed Jun 16, 2022
Insider Transaction Report
Form 4
Shearman Mark S
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-06-15$10.06/sh−5,145$51,745→ 68,349 total
Footnotes (1)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 19, 2021 and represents the sale of shares necessary to meet tax withholding obligations as a result of vesting in restricted stock units and in performance stock units on June 14, 2022. The sale does not represent a discretionary trade by the Reporting Person.